2021 Revenues ($USD) : $27,305,000,000
2021 R&D spend : $5,363,000,000
2021 Number of Employees : 14,400
Fiscal Year End : 12/31/2021
Leader : CEO Daniel O’Day

Gilead Sciences became the first company to win FDA approval for a COVID-19 therapy with Veklury (remdesivir) on October 22, 2020. Strong sales of the drug in 2021 more than made up for the negative impact of COVID-19 on the company’s HIV and Hepatitis C drugs. The Forest City, California–based company announced in February 2022 that the drug maintained efficacy against omicron and other SARS-CoV-2 variants. Gilead won seven approvals or accelerated approvals in the U.S. and Europe in 2021. In 2021, the company completed its acquisition of MYR GmbH for approximately €1.45 billion. In 2020, the firm acquired the immune-oncology company Forty Seven for $4.9 billion. —BB